Objective: To determine the objective neurocognitive effects of (1) single-dose ketamine, (2) repeated-dose ketamine, (3) ketamine adjunct to electroconvulsive therapy (ECT), and (4) ketamine as the anesthetic for ECT in major depressive disorder (MDD) and depression in bipolar disorder (BD).
Data Sources: Cochrane, MEDLINE, Embase, and PsycINFO databases were searched on March 19, 2020 (updated July 2, 2020), using the terms terms major depressive disorderbipolar disorder and ketamine and their synonyms. Clinical trial registries (search date May 4, 2020) and reference sections of included articles were also searched. There was no restriction on language or year of publication.
Study Selection: Of 4,035 identified articles, 17 met inclusion criteria. Controlled and open-label studies of adults who received at least 1 ketamine treatment for a current major depressive episode, as part of MDD or BD, were included. Only studies measuring cognition using at least 1 validated, objective neurocognitive assessment were eligible.
Data Extraction: Results are presented using a narrative review format. Data regarding change in cognitive performance from baseline to end-of-treatment and/or differences in cognition between ketamine and control groups were extracted.
Results: There were no negative effects of single- or repeated-dose intravenous ketamine up to 2 weeks post-treatment in MDD. Limited data were available for BD populations, as well as on other routes of ketamine administration.
Conclusions: Data to definitively answer the question of whether ketamine has substantive or persistent cognitive effects are insufficient; thus, larger controlled trials measuring cognition as the primary outcome are needed. Future research should focus on different routes of ketamine administration, ketamine enantiomers, and BD populations.
Continue Reading...
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
James SL, Abate D, Abate KH, et al; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018;392(10159):1789–1858. PubMedCrossRef
Nemeroff CB. Prevalence and management of treatment-resistant depression.J Clin Psychiatry. 2007;68(suppl 8):17–25. PubMed
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry. 2006;163(11):1905–1917. PubMedCrossRef
Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.Ann Intern Med. 2011;155(11):772–785. PubMedCrossRef
Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada.Can J Psychiatry. 2014;59(7):349–357. PubMedCrossRef
Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care.Anesth Essays Res. 2014;8(3):283–290. PubMedCrossRef
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients.Biol Psychiatry. 2000;47(4):351–354. PubMedCrossRef
Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. PubMedCrossRef
Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–256. PubMedCrossRef
Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802. PubMedCrossRef
Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–946. PubMedCrossRef
Zheng W, Zhou Y-L, Liu W-J, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res. 2018;106:61–68. PubMedCrossRef
Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150–158. PubMedCrossRef
Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D. 2015;15(1):37–43. PubMedCrossRef
Andrade C. Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852–e857. PubMedCrossRef
Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Can J Psychiatry. 2021;66(2):113–125. PubMedCrossRef
Vaccarino SR, Kennedy SH. Treatment Resistant Depression. In: Vasquez GH, Zarate CA, Brietzke E, eds. Ketamine for Treatment Resistant Depression: Neurobiology and Applications. Academic Press; 2020:33-84.
Phillips JL, Jaworska N, Kamler E, et al; CAN-BIND Investigator Team. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry. 2020;20(1):268. PubMedCrossRef
Vidal S, Gex-Fabry M, Bancila V, et al. Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg/kg in treatment-resistant major depression: an open 4-week longitudinal study. J Clin Psychopharmacol. 2018;38(6):590–597. PubMedCrossRef
Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142. PubMedCrossRef
Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82. PubMedCrossRef
Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014;155(1):123–129. PubMedCrossRef
aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145. PubMedCrossRef
Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176(5):401–409. PubMedCrossRef
Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542–555. PubMedCrossRef
Ghoneim MM, Hinrichs JV, Mewaldt SP, et al. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol. 1985;5(2):70–77. PubMedCrossRef
D’Souza DC, Ahn K, Bhakta S, et al. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry. 2012;72(9):785–794. PubMedCrossRef
Harborne GC, Watson FL, Healy DT, et al. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy J Psychopharmacol. 1996;10(2):134–140. PubMedCrossRef
Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14(5):301–307. PubMedCrossRef
Zhang C, Xu Y, Zhang B, et al. Cognitive impairment in chronic ketamine abusers. Psychiatry Res. 2020;291:113206. PubMedCrossRef
Ke X, Ding Y, Xu K, et al. The profile of cognitive impairments in chronic ketamine users. Psychiatry Res. 2018;266:124–131. PubMedCrossRef
Chan KWS, Lee TMC, Siu AMH, et al. Effects of chronic ketamine use on frontal and medial temporal cognition. Addict Behav. 2013;38(5):2128–2132. PubMedCrossRef
Morgan CJA, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188(4):408–424. PubMedCrossRef
Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–2040. PubMedCrossRef
Martínez-Arán A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004;161(2):262–270. PubMedCrossRef
McGirr A, Berlim MT, Bond DJ, et al. Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. Br J Psychiatry. 2017;210(6):403–407. PubMedCrossRef
MacPherson RD, Loo CK. Cognitive impairment following electroconvulsive therapy–does the choice of anesthetic agent make a difference? J ECT. 2008;24(1):52–56. PubMedCrossRef
Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78. PubMedCrossRef
Crisanti C, Enrico P, Fiorentini A, et al. Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies. J Affect Disord. 2020;276:1109–1118. PubMedCrossRef
Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–382. PubMedCrossRef
Meader N, King K, Llewellyn A, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3(1):82. PubMedCrossRef
McDaniel WW, Sahota AK, Vyas BV, et al. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J ECT. 2006;22(2):103–106. PubMedCrossRef
Rybakowski JK, Bodnar A, Krzywotulski M, et al. Ketamine anesthesia, efficacy of electroconvulsive therapy, and cognitive functions in treatment-resistant depression. J ECT. 2016;32(3):164–168. PubMedCrossRef
Zhong X, He H, Zhang C, et al. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. J Affect Disord. 2016;201:124–130. PubMedCrossRef
Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, et al. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. 2015;48(2):78–79. PubMedCrossRef
Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40(5):1084–1090. PubMedCrossRef
Chen M-H, Li C-T, Lin W-C, et al. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord. 2018;241(201):1–7. PubMedCrossRef
Grunebaum MF, Ellis SP, Keilp JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017;19(3):176–183. PubMedCrossRef
Zhou Y, Zheng W, Liu W, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol. 2018;32(10):1118–1126. PubMedCrossRef
Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–1813. PubMedCrossRef
Zheng W, Zhou Y-L, Liu W-J, et al. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord. 2019;246:241–247. PubMedCrossRef
Liu W, Zhou Y, Zheng W, et al. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord. 2019;259:1–6. PubMedCrossRef
Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label Study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3):19m12891. PubMedCrossRef
Anderson IM, Blamire A, Branton T, et al; Ketamine-ECT Study team. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry. 2017;4(5):365–377. PubMedCrossRef
Loo CK, Katalinic N, Garfield JBB, et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012;142(1-3):233–240. PubMedCrossRef
Altinay M, Karne H, Anand A. Administration of sub-anesthetic dose of ketamine and electroconvulsive treatment on alternate week days in patients with treatment resistant depression: a double blind placebo controlled trial. Psychopharmacol Bull. 2019;49(1):8–16. PubMed
Chen Q, Min S, Hao X, et al. Effect of low dose of ketamine on learning memory function in patients undergoing electroconvulsive therapy-a randomized, double-blind, controlled clinical study. J ECT. 2017;33(2):89–95. PubMedCrossRef
Jagtiani A, Khurana H, Malhotra N. Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major Indian J Psychiatry. 2019;61(3):258–264. PubMedCrossRef
Carspecken CW, Borisovskaya A, Lan S-T, et al. Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: a randomized clinical trial. J Neurosurg Anesthesiol. 2018;30(4):305–313. PubMedCrossRef
Yoosefi A, Sepehri AS, Kargar M, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J ECT. 2014;30(1):15–21. PubMedCrossRef
Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244–254. PubMedCrossRef
Lisanby SH, Maddox JH, Prudic J, et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry. 2000;57(6):581–590. PubMedCrossRef
Fraser LM, O’Carroll RE, Ebmeier KP. The effect of electroconvulsive therapy on autobiographical memory: a systematic review. J ECT. 2008;24(1):10–17. PubMedCrossRef
Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 1995;13(4):335–345. PubMedCrossRef
Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244(4910):1360–1362. PubMedCrossRef
Brunamonti E, Mione V, Di Bello F, et al. The NMDAr antagonist ketamine interferes with manipulation of information for transitive inference reasoning in non-human primates. J Psychopharmacol. 2014;28(9):881–887. PubMedCrossRef
Blackman RK, Macdonald AW 3rd, Chafee MV. Effects of ketamine on context-processing performance in monkeys: a new animal model of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2013;38(11):2090–2100. PubMedCrossRef
Kos T, Nikiforuk A, Rafa D, et al. The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice. Psychopharmacology (Berl). 2011;214(4):911–921. PubMedCrossRef
Nikiforuk A, Hołuj M, Kos T, et al. The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia. Neuropharmacology. 2016;105:351–360. PubMedCrossRef
Patton MS, Lodge DJ, Morilak DA, et al. Ketamine corrects stress-induced cognitive dysfunction through JAK2/STAT3 signaling in the orbitofrontal cortex. Neuropsychopharmacology. 2017;42(6):1220–1230. PubMedCrossRef
Papp M, Gruca P, Lason-Tyburkiewicz M, et al. Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression. Behav Pharmacol. 2017;28(1):1–8. PubMedCrossRef
Jett JD, Boley AM, Girotti M, et al. Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology (Berl). 2015;232(17):3123–3133. PubMedCrossRef
Gass N, Becker R, Reinwald J, et al. Differences between ketamine’s short-term and long-term effects on brain circuitry in depression. Transl Psychiatry. 2019;9(1):172. PubMedCrossRef
Lee Y, Syeda K, Maruschak NA, et al. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. J Clin Psychopharmacol. 2016;36(1):50–56. PubMedCrossRef
Zhang MWB, Ho RCM. Controversies of the effect of ketamine on cognition. Front Psychiatry. 2016;7:47. PubMedCrossRef
Koffler SP, Hampstead BM, Irani F, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol. 2007;22(6):719–729. PubMedCrossRef
Kim M, Cho S, Lee J-H. The effects of long-term ketamine treatment on cognitive function in complex regional pain syndrome: a preliminary study. Pain Med. 2016;17(8):1447–1451. PubMedCrossRef
Ersek M, Cherrier MM, Overman SS, et al. The cognitive effects of opioids. Pain Manag Nurs. 2004;5(2):75–93. PubMedCrossRef
Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf. 2015;14(8):1291–1304. PubMedCrossRef
Hasselbalch BJ, Knorr U, Hasselbalch SG, et al. The cumulative load of depressive illness is associated with cognitive function in the remitted state of unipolar depressive disorder. Eur Psychiatry. 2013;28(6):349–355. PubMedCrossRef
Murrough JW, Iacoviello B, Neumeister A, et al. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011;96(4):553–563. PubMedCrossRef
Bhalla RK, Butters MA, Mulsant BH, et al. Persistence of neuropsychologic deficits in the remitted state of late-life depression. Am J Geriatr Psychiatry. 2006;14(5):419–427. PubMedCrossRef
Fernie G, Currie J, Perrin JS, et al. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. Br J Psychiatry. 2017;210(6):422–428. PubMedCrossRef
Loo CK, Gálvez V, O’Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48–56. PubMedCrossRef
Rasmussen KG, Kung S, Lapid MI, et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014;215(2):362–365. PubMedCrossRef
Ray-Griffith SL, Eads LA, Han X, et al. A randomized pilot study comparing ketamine and methohexital anesthesia for electroconvulsive therapy in patients with depression. J ECT. 2017;33(4):268–271. PubMedCrossRef
Dong J, Min S, Qiu H, et al. Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: A randomized controlled trial. Psychiatry Res. 2019;281:112573. PubMedCrossRef
Zhang M, Rosenheck R, Lin X, et al. A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. J Affect Disord. 2018;227:372–378. PubMedCrossRef
Basso L, Bönke L, Aust S, et al. Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients. J Psychiatr Res. 2020;123:1–8. PubMedCrossRef
Wilkinson ST, Katz RB, Toprak M, et al. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric J Clin Psychiatry. 2018;79(4):17m11731. PubMedCrossRef
Murrough JW, Wan L-B, Iacoviello B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl). 2013;231(3):481–488. PubMedCrossRef
Otto MW, Fava M, Penava SJ, et al. Life event, mood, and cognitive predictors of perceived stress before and after treatment for major depression. Cognit Ther Res. 1997;21(4):409–420. CrossRef
Pan Z, Park C, Brietzke E, et al. Cognitive impairment in major depressive disorder. CNS Spectr. 2019;24(1):22–29. PubMedCrossRef
Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysi J Psychiatr Res. 2004;38(1):27–35. PubMedCrossRef
Gomez RG, Fleming SH, Keller J, et al. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol Psychiatry. 2006;60(5):472–478. PubMedCrossRef
Ebert B, Mikkelsen S, Thorkildsen C, et al. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol. 1997;333(1):99–104. PubMedCrossRef
Vollenweider FX, Leenders KL, Øye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7(1):25–38. PubMedCrossRef
Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002;96(2):357–366. PubMedCrossRef
Kolp E, Friedman HL, Krupitsky E, et al. Ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications. Int J Transpers Stud. 2014;33(2):84–140. CrossRef
Dore J, Turnipseed B, Dwyer S, et al. Ketamine assisted psychotherapy (kap): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs. 2019;51(2):189–198. PubMedCrossRef